Centessa Pharmaceuticals CNTA 深 沪
等待开盘 07-02 09:30:00 美东时间
40.50
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 40.50
- 总市值 62.67亿
- 52周最高 40.56
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 13.22
- 委 比 0.00%
- 总股本 1.55亿
- 历史最高 40.56
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.885
- 每 手 1
- 风险率 8.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Record-setting healthcare M&A activity to extend through H2: PwC
Healthcare dealmaking is already at the highest level since the pandemic, and the momentum is expected to continue into H2 2026, driven by looming patent cliffs and consumer demand for areas such as w...
06-26 01:59
礼来完成对Centessa Pharmaceuticals的收购 布局嗜睡症治疗领域
礼来（LLY）完成对临床阶段生物制药企业森特萨制药（CNTA）的收购，聚焦后者的食欲素2受体激动剂管线，发力发作性睡病等觉醒-睡眠障碍、相关神经类疾病的创新疗法...
06-24 20:56
Lilly completes acquisition of Centessa Pharmaceuticals
Lilly completes acquisition of Centessa Pharmaceuticals Eli Lilly completed its acquisition of Centessa Pharmaceuticals, adding a clinical-stage portfolio focused on orexin receptor 2 agonists. The deal expands Lilly’s push into treatments for narcolepsy, with potential applications across other sle
06-24 20:46
礼来78亿美元收购Centessa Pharma案获高等法院批准
礼来78亿美元收购Centessa制药的交易已获得高等法院批准，扫清核心监管障碍，向落地迈出关键一步。 Centessa股东可获每股38.00美元现金，以及最...
06-23 14:46
Centessa Pharmaceuticals' Proposed $38/Share Acquisition By Eli Lilly Receives High Court Of Justice Of England And Wales Approval
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, which entered into a definitive agreement on March 31, 2026 relating to its proposed acquisition by Eli Lilly...
06-23 04:08
Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales
Centessa Pharmaceuticals has been approved by the High Court of England and Wales for acquisition by Eli Lilly and Company for $38 per share plus a CVR, totaling approximately $7.8 billion. The transaction is set to close on June 24, 2026, with Centessa ADSs ceasing trading on June 23.
06-22 20:05
礼来的两套BD策略，对中国Biotech的启示
本文系基于公开资料撰写，仅作为信息交流之用，不构成任何投资建议 今年年初，礼来以最高23亿美元收购了Ajax Therapeutics。它的核心资产包括...
06-16 07:28
Centessa Shareholders Approve Eli Lilly Acquisition Scheme
An update from Centessa Pharmaceuticals ( ($CNTA) ) is now available. On June 1...
06-13 06:32
Novo Nordisk CEO Hints Semaglutide Could Be More Than A Weight-Loss Drug: 'A Bit Of A Longevity Game'
Novo Nordisk exploring additional uses for obesity drug semaglutide, including potential for longevity and aesthetics.
06-08 17:07
“并购狂人”礼来扫货加速：年内8起并购落地，总额达245亿美元
今年以来，礼来每个月都在“买买买”。 全球减肥药巨头礼来今年以来的并购节凑，似乎有些停不下来。 当地时间5月26日，礼来一举宣布了三项并购，分别并购Cure...
05-27 15:44
